Accéder au contenu
Merck

Distribution and medical impact of loss-of-function variants in the Finnish founder population.

PLoS genetics (2014-08-01)
Elaine T Lim, Peter Würtz, Aki S Havulinna, Priit Palta, Taru Tukiainen, Karola Rehnström, Tõnu Esko, Reedik Mägi, Michael Inouye, Tuuli Lappalainen, Yingleong Chan, Rany M Salem, Monkol Lek, Jason Flannick, Xueling Sim, Alisa Manning, Claes Ladenvall, Suzannah Bumpstead, Eija Hämäläinen, Kristiina Aalto, Mikael Maksimow, Marko Salmi, Stefan Blankenberg, Diego Ardissino, Svati Shah, Benjamin Horne, Ruth McPherson, Gerald K Hovingh, Muredach P Reilly, Hugh Watkins, Anuj Goel, Martin Farrall, Domenico Girelli, Alex P Reiner, Nathan O Stitziel, Sekar Kathiresan, Stacey Gabriel, Jeffrey C Barrett, Terho Lehtimäki, Markku Laakso, Leif Groop, Jaakko Kaprio, Markus Perola, Mark I McCarthy, Michael Boehnke, David M Altshuler, Cecilia M Lindgren, Joel N Hirschhorn, Andres Metspalu, Nelson B Freimer, Tanja Zeller, Sirpa Jalkanen, Seppo Koskinen, Olli Raitakari, Richard Durbin, Daniel G MacArthur, Veikko Salomaa, Samuli Ripatti, Mark J Daly, Aarno Palotie
RÉSUMÉ

Exome sequencing studies in complex diseases are challenged by the allelic heterogeneity, large number and modest effect sizes of associated variants on disease risk and the presence of large numbers of neutral variants, even in phenotypically relevant genes. Isolated populations with recent bottlenecks offer advantages for studying rare variants in complex diseases as they have deleterious variants that are present at higher frequencies as well as a substantial reduction in rare neutral variation. To explore the potential of the Finnish founder population for studying low-frequency (0.5-5%) variants in complex diseases, we compared exome sequence data on 3,000 Finns to the same number of non-Finnish Europeans and discovered that, despite having fewer variable sites overall, the average Finn has more low-frequency loss-of-function variants and complete gene knockouts. We then used several well-characterized Finnish population cohorts to study the phenotypic effects of 83 enriched loss-of-function variants across 60 phenotypes in 36,262 Finns. Using a deep set of quantitative traits collected on these cohorts, we show 5 associations (p<5×10⁻⁸) including splice variants in LPA that lowered plasma lipoprotein(a) levels (P = 1.5×10⁻¹¹⁷). Through accessing the national medical records of these participants, we evaluate the LPA finding via Mendelian randomization and confirm that these splice variants confer protection from cardiovascular disease (OR = 0.84, P = 3×10⁻⁴), demonstrating for the first time the correlation between very low levels of LPA in humans with potential therapeutic implications for cardiovascular diseases. More generally, this study articulates substantial advantages for studying the role of rare variation in complex phenotypes in founder populations like the Finns and by combining a unique population genetic history with data from large population cohorts and centralized research access to National Health Registers.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Chlorure de magnésium, anhydrous, ≥98%
Sigma-Aldrich
Chlorure de magnésium solution, for molecular biology, 1.00 M±0.01 M
Sigma-Aldrich
Chlorure de magnésium, powder, <200 μm
Sigma-Aldrich
Chlorure de magnésium solution, BioUltra, for molecular biology, 2 M in H2O
Sigma-Aldrich
Chlorure de magnésium, BioReagent, suitable for insect cell culture, ≥97.0%
Sigma-Aldrich
Chlorure de magnésium solution, PCR Reagent, 25 mM MgCI2 solution for PCR
Sigma-Aldrich
Chlorure de magnésium, AnhydroBeads, −10 mesh, 99.9% trace metals basis
Sigma-Aldrich
Chlorure de magnésium solution, BioUltra, for molecular biology, ~1 M in H2O
Sigma-Aldrich
Chlorure de magnésium, AnhydroBeads, −10 mesh, 99.99% trace metals basis
Sigma-Aldrich
Chlorure de magnésium solution, 0.1 M
Sigma-Aldrich
Chlorure de magnésium solution, BioUltra, for molecular biology, ~0.025 M in H2O